sofosbuvir velpatasvir voxilaprevir drug combination

Also Known As:

Vosevi; sofosbuvir - velpatasvir - voxilaprevir; sofosbuvir, velpatasvir and voxilaprevir

Networked: 54 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleotides: 48
      - Uracil Nucleotides: 40
        Uridine Monophosphate: 182
        Sofosbuvir: 1518
        sofosbuvir velpatasvir voxilaprevir drug combination: 54
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - sofosbuvir velpatasvir voxilaprevir drug combination: 54
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Ribonucleotides: 307
    - Uracil Nucleotides: 40
      - Uridine Monophosphate: 182
        Sofosbuvir: 1518
        sofosbuvir velpatasvir voxilaprevir drug combination: 54
  - Pyrimidine Nucleotides: 48
    - Uracil Nucleotides: 40
      - Uridine Monophosphate: 182
        Sofosbuvir: 1518
        sofosbuvir velpatasvir voxilaprevir drug combination: 54
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Carbamates: 945
      - sofosbuvir velpatasvir voxilaprevir drug combination: 54
Pharmaceutical Preparations
- Drug Combinations: 5337
  - sofosbuvir velpatasvir voxilaprevir drug combination: 54
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - sofosbuvir velpatasvir voxilaprevir drug combination: 54

Experts

1.	Brainard, Diana M: 6 articles (01/2019 - 01/2017)
2.	Dvory-Sobol, Hadas: 5 articles (01/2019 - 01/2017)
3.	Hyland, Robert H: 5 articles (01/2019 - 01/2017)
4.	Stamm, Luisa M: 5 articles (01/2019 - 01/2017)
5.	McHutchison, John G: 4 articles (01/2018 - 01/2017)
6.	Manns, Michael P: 3 articles (09/2020 - 01/2017)
7.	Zeuzem, Stefan: 3 articles (09/2020 - 01/2017)
8.	Reddy, K Rajender: 3 articles (01/2018 - 01/2017)
9.	Subramanian, G Mani: 3 articles (01/2018 - 01/2017)
10.	Dore, Gregory J: 2 articles (05/2022 - 01/2017)

Related Diseases

1.	Infections 01/01/2022 - "The pangenotypic regimen of sofosbuvir-velpatasvir-voxilaprevir is highly efficacious and well-tolerated in treating chronic HCV infection in adolescents." 01/01/2017 - "Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials." 01/01/2022 - "Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. " 01/01/2022 - "Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection." 01/01/2018 - "To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection. "
2.	Chronic Hepatitis C 10/01/2019 - "Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs." 04/01/2018 - "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C." 01/01/2018 - "Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1." 10/01/2022 - "Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection." 01/01/2021 - "Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C virus (HCV) infected patients who have previously experienced a direct-acting antiviral (DAA) containing regimen. "
3.	Hepatitis C 01/01/2022 - "Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry." 12/01/2019 - "Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure." 06/01/2019 - "Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C." 01/01/2019 - "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C." 05/01/2018 - "Areas covered: Sofosbuvir/velpatasvir/voxilaprevir is a recently approved therapeutic combination for the treatment of hepatitis C. "
4.	Virus Diseases (Viral Diseases) 01/01/2022 - "Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial." 04/01/2023 - "Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan." 01/01/2021 - "Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals."
5.	Hepatitis 01/01/2018 - "Biochemical Basis of Vosevi, a New Treatment for Hepatitis CPublished as part of the Biochemistry series "Biochemistry to Bedside"." 12/28/2020 - "The patient developed acute alloimmune hepatitis approximately 2 weeks after starting treatment with sofosbuvir, velpatasvir, and voxilaprevir. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Sofosbuvir
3.	velpatasvir
4.	Tablets
5.	Ribavirin (Virazole)
6.	glecaprevir and pibrentasvir
7.	grazoprevir
8.	sofosbuvir drug combination ledipasvir
9.	elbasvir
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Retreatment
2.	Therapeutics
3.	Transjugular Intrahepatic Portasystemic Shunt
4.	Salvage Therapy
5.	Liver Transplantation